Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 16/20 | 0.45 |
| ▸ | FPR2 | P25090 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL168402 | 0.91 | KMT2A (0.54) | KMT2AKDM4EL3MBTL1SCN9A | |
| SCHEMBL5962999 | 0.87 | SCN9A (0.51) | SCN4AKMT2ASCN9A | |
| SCHEMBL30231293 | 0.81 | PARP10 (0.45) | SCN4ASCN9AFPR2 | |
| SCHEMBL28088814 | 0.81 | ALDH1A1 (0.51) | KMT2AL3MBTL1SCN9A | |
| SCHEMBL5963146 | 0.79 | SCN9A (0.57) | SCN4ASCN9AFPR2 | |
| SCHEMBL15090773 | 0.77 | SCN9A (0.46) | KMT2AKDM4EL3MBTL1SCN9A | |
| SCHEMBL14150735 | 0.77 | KMT2A (0.64) | KMT2AKDM4EL3MBTL1 | |
| SCHEMBL19778587 | 0.75 | KMT2A (0.54) | KMT2AKDM4EL3MBTL1 | |
| SCHEMBL30078274 | 0.75 | ALDH1A1 (0.50) | KMT2AKDM4EL3MBTL1SCN9A | |
| SCHEMBL725497 | 0.75 | CYP2C9 (0.53) | KMT2AKDM4EL3MBTL1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1292577-B1 | ARYL SUBSTITUTED PYRAZOLES, TRIAZOLES AND TETRAZOLES AS SODIUM CHANNEL BLOCKER | EURO CELTIQUE SA (LU) | 2012-10-24 | — | — | EP | disclosed |
| US-7078426-B2 | Aryl substituted pyrazoles, triazoles, and tetrazoles, and the use thereof | EURO-CELTIQUE S.A. (LU) | 2006-07-18 | — | — | US | disclosed |
| US-6919363-B2 | Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof | EURO-CELTIQUE S.A. (LU) | 2005-07-19 | — | — | US | disclosed |
| US-20040002523-A1 | Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof | EURO-CELTIQUE S.A. | 2004-01-01 | — | — | US | disclosed |
| EP-1292577-A2 | ARYL SUBSTITUTED PYRAZOLES, TRIAZOLES AND TETRAZOLES AS SODIUM CHANNEL BLOCKER | Euro-Celtique S.A. (LU) | 2003-03-19 | — | — | EP | disclosed |
| US-20020006947-A1 | Aryl substituted pyrazoles, triazoles, and tetrazoles, and the use thereof | PURDUE PHARMA L.P. | 2002-01-17 | — | — | US | disclosed |
| WO-2001072714-A2 | ARYL SUBSTITUTED PYRAZOLES, TRIAZOLES AND TETRAZOLES AS SODIUM CHANNEL BLOCKER | EURO-CELTIQUE S.A. (LU) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002523-A1 | Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof | CACNA1I, GRIK5, SOD1 | SCN4A 529/4885KMT2A 3581/4885KDM4E 3325/4885 |
| US-20020006947-A1 | Aryl substituted pyrazoles, triazoles, and tetrazoles, and the use thereof | GRIK5, CACNA1I, SOD1 | SCN4A 621/4885KMT2A 3602/4885KDM4E 3213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.